Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 01.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 17.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Form 8-K. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 16.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compen |
| 03.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compen |
| 27.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | xchange Commission. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 19.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ( |
| 08.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp |
| 14.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp |
Stammdaten
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Unternehmen & Branche
| Name | Xenon Pharmaceuticals Inc. |
|---|---|
| Ticker | XENE |
| CIK | 0001582313 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 4,31 Mrd. USD |
| Beta | 0,75 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -345,910,000 | -4.36 | 633,163,000 | 581,760,000 | |
| 2025-09-30 | 10-Q | -90,896,000 | -1.15 | 607,836,000 | 559,511,000 | |
| 2025-06-30 | 10-Q | -84,706,000 | -1.07 | 674,281,000 | 633,978,000 | |
| 2025-03-31 | 10-Q | -65,047,000 | -0.83 | 743,280,000 | 703,957,000 | |
| 2024-12-31 | 10-K | -234,330,000 | -3.01 | 798,139,000 | 754,903,000 | |
| 2024-09-30 | 10-Q | -62,790,000 | -0.81 | 835,901,000 | 797,807,000 | |
| 2024-06-30 | 10-Q | -57,924,000 | -0.75 | 884,011,000 | 844,047,000 | |
| 2024-03-31 | 10-Q | -47,931,000 | -0.62 | 919,023,000 | 887,698,000 | |
| 2023-12-31 | 10-K | -182,393,000 | -2.73 | 964,798,000 | 927,921,000 | |
| 2023-09-30 | 10-Q | -48,462,000 | -0.73 | 671,093,000 | 636,592,000 | |
| 2023-06-30 | 10-Q | -47,461,000 | -0.72 | 684,899,000 | 646,457,000 | |
| 2023-03-31 | 10-Q | -41,727,000 | -0.63 | 719,868,000 | 686,944,000 | |
| 2022-12-31 | 10-K | -125,373,000 | -2.06 | 754,146,000 | 721,497,000 | |
| 2022-09-30 | 10-Q | -37,150,000 | -0.57 | 775,813,000 | 753,119,000 | |
| 2022-06-30 | 10-Q | -31,158,000 | -0.55 | 807,380,000 | 785,793,000 | |
| 2022-03-31 | 10-Q | -19,670,000 | -0.35 | 558,059,000 | 541,853,000 | |
| 2021-12-31 | 10-K | -78,882,000 | -1.77 | 572,007,000 | 550,033,000 | |
| 2021-09-30 | 10-Q | -15,445,000 | -0.36 | 264,353,000 | 248,939,000 | |
| 2021-06-30 | 10-Q | -22,109,000 | -0.51 | 274,711,000 | 256,983,000 | |
| 2021-03-31 | 10-Q | -15,764,000 | 290,671,000 | 276,277,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-06-05 | GANNON STEVEN | Director | Open Market Sale | -3 | 30.48 | -91.44 | -100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.